Bone marrow transplant-associated thrombotic microangiopathy (BMT-TM), usually associated with thrombocytopenia, microangiopathic haemolytic anaemia (MAHA) and renal insufficiency, has been reported to occur approximately 5-6 months after BMT. We report a case of relapsed malignant lymphoma complicated by BMT-TM of hyperacute onset, which has never been described in the literature. Our patient, a 52-yearold male, developed MAHA with gross haematuria, thrombocytopenia, lactate dehydrogenase elevation and renal insufficiency 2 days after autologous PBSC transplantation following high-dose chemotherapy. Supportive treatment, ie glucocorticoid, fresh frozen plasma and haemodiafiltration were given, and thereafter the BMT-TM gradually improved. In heavily pretreated patients, caution should be exercised for possible occurrence of the BMT-TM of hyperacute onset.
Thrombotic microangiopathy (TM) in association with BMT (BMT-TM) has been reported by several investigators. 1, 2 In the setting of allogeneic BMT, not only conditioning therapy, but also CsA, GVHD and cytomegalovirus (CMV) infection are incriminated as possible factors in the pathogenesis of BMT-TM. 1, 2 In autologous BMT, conditioning therapy has been proposed as a cause. 2 Although conditioning-associated TM is generally thought to occur approximately 5-6 months after BMT, 2 we report a case of hyperacute onset (during high-dose chemotherapy (HDC) ) TM following autologous PBSC transplantation (PBSCT). Such hyperacute onset BMT-TM has never been reported in the literature.
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Case report
A 52-year-old man was diagnosed as having stage IV peripheral T cell lymphoma involving retroperitoneal lymph nodes, liver, spleen, and bone marrow in May 1994. He received several regimens of combination chemotherapy (MACOP-B, consisting of methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisolone and bleomycin; CHOP, consisting of cyclophosphamide, doxorubicin, vincristine and prednisolone; CHOP-bleo, consisting of CHOP with bleomycin), which produced some response, but his disease progressed and he was referred to our hospital in April 1996. Salvage chemotherapy consisting of etoposide, methylprednisolone, high-dose cytarabine and cisplatin (ESHAP) 3 produced a partial response. The harvested PBSC which were enriched for CD34 + cells were cryopreserved as previously described. 4 Organ function remained within normal limits before the patient received HDC with PBSCT.
In August 1996, he was treated with high-dose carboplatin ) and dexamethazone (40 mg/day (total dose 200 mg) ) on 5 consecutive days (days Ϫ7 to Ϫ3). Vomiting and diarrhoea observed during the HDC were considered maximal grade 2 toxicities according to the National Cancer Institute Common Toxicity Criteria. Mild proteinuria developed on day Ϫ3. A febrile episode occurred on day Ϫ2, and empiric antibiotic therapy was started. On day 0, mild lactate dehydrogenase (LDH) elevation (566 U/l, normal range 234-484 U/l) was observed. His post-transplant course is shown in Figure 1 . Abrupt onset anaemia (Hb 101 g/l, Ht 29%) and thrombocytopenia (6 × 10 9 /l) were recognized on day 2, and other laboratory values were LDH, 1268 U/l; haptoglobin, Ͻ0.01 g/l; direct antiglobulin test, negative; prothrombin time, 10.7 s (normal range 10.8-13.0 s); activated partial thromboplastin time, 27.1 s (normal range 20-35 s); fibrin split products, normal; serum creatinine, 80 mm/l (normal range 44-97 mm/l); 2+ reaction for albumin and 3+ reaction for red blood cells in the urine; proteinuria, 8.2 g/day. A peripheral blood smear showed 6.4% schistocytes, and a diagnosis of TM was made. Because severe neutropenia was persistent, we did not perform a plasma exchange but administered four units of fresh frozen plasma (FFP) per day and prednisolone (1 mg/kg) empirically. On day 3, gross haematuria began, and we thus administered human haptoglobin concentrates to prevent renal toxicity due to massive intravascular haemolysis. When his WBC recovered (5.8 × 10 9 /l) on day 9 with G-CSF support, he suffered from generalized edema, his body weight rose by about 10 kg, and a chest X-ray showed cardiomegaly and pulmonary congestion. We therefore began continuous haemodiafiltration (CHDF) with nafamostat mesilate (FUT) as an anticoagulant. After the initiation of the CHDF and FUT therapy, LDH values and transfusion requirements gradually decreased. The CHDF was stopped on day 38. Signs of haemolysis disappeared over 3 months and the last platelet transfusion was given on day 78. The patient was discharged from hospital on day 169. His laboratory values 11 months after the onset of BMT-TM were as follows: Hb, 83 g/l; PLTS, 57 × 10 9 /l; LDH, 424 U/l; serum creatinine, 180 mm/l; BUN, 13.2 mm/l.
Discussion
Byrnes et al 1 recently reviewed more than 90 cases of BMT-TM. It is thought to occur at a median interval of 5-6 months after BMT, more frequently after allogeneic transplantation.
1,2 TBI has been reported to be an important causal factor of BMT-TM. 1 Therefore, BMT-TM without TBI preparation has been regarded as unusual. However, recently Fisher and colleagues 5 reported that 15 (2.6%) of the 581 breast cancer patients who underwent autologous transplants conditioned without TBI developed late onset BMT-TM. Table 1 shows the characteristics of the 27 patients with BMT-TM (26 reported cases [6] [7] [8] [9] [10] [11] and the present case 12 ) who underwent autologous transplants conditioned without TBI. The median onset of the BMT-TM in these cases was 5 months after transplantation, but only one patient conditioned with CY, BCNU and etoposide (CBV) presented with BMT-TM 11 days after PBSCT. 12 The severity of BMT-TM in that patient was grade 4, according to the grading system of BMT-TM proposed by Zeigler and colleagues. 12 The patient did not respond to a cryosupernatant plasma exchange (PE) or to Staphylococcal protein A immunoabsorption (SPAI). In our patient, the onset of BMT-TM was much earlier than in the previously reported cases ( Table 1 ). The severity of the BMT-TM in our patient was grade 3 at diagnosis and subsequently worsened to grade 4 (maximal percentage of schistocytes in the peripheral blood was 11.3%).
Because the interval between the last administration of the ESHAP regimen and the onset of TM was very short in the present patient (ie 5 weeks), the anticancer agents utilized in the ESHAP regimen and the HDC could have operated additively in the pathogenesis of the BMT-TM. In addition, there remains a possibility that the prior ESHAP regimen might have directly caused the TM. Vascular toxicity associated with some anticancer agents is wellknown, 13 and mitomycin C, cisplatin, carboplatin and bleomycin in conventional doses have been described as causal agents of TM. The acute form of cancer chemotherapyassociated haemolytic uremic syndrome (C-HUS) is characterized by a fulminant course with marked microangiopathic changes, severe haemolysis and thrombocytopenia, and rapidly progressive renal failure. In light of the hyperacute onset and clinical severity, the BMT-TM in this patient is thought to have characteristics similar to those of acute form C-HUS. Although haemolysis and elevated LDH could be multifactorial and due to repeated transfusions, infection and G-CSF administration, the present case is thought to fulfil the minimum criteria of TM 5 as follows: (1) evidence of microangiopathic haemolysis with schistocytes on peripheral blood smear, an elevation in serum LDH levels and a persistent decline in haematocrit; (2) sudden decrease in platelet counts which persisted for at least 2 weeks; (3) negative direct and indirect antiglobulin tests; and (4) negative testing for disseminated intravascular coagulation.
There has been no effective therapy against fulminant BMT-TM and acute onset C-HUS, although some pilot studies regarding cryosupernatant PE and SPAI have shown promising results. 5, 6, 8, 9, 12 BMT-TM in the present patient gradually improved after administration of FFP and glucocorticoid, and other supportive measures. We used nafamostat mesilate (FUT) as the anticoagulant during CHDF, because it has been reported to be useful for haemodialysis in patients with a high risk of bleeding such as those with thrombocytopenia.
14 As the haemolysis in our patient obviously improved after the initiation of CHDF (Figure 1) , FUT might have shown some efficacy by inhibiting complement activation. 15 In conclusion, the present case indicates that BMT-TM can occur during or immediately after HDC. In heavily pretreated patients, possible occurrence of the BMT-TM of hyperacute onset should be considered.
